STERIS plc (NYSE:STE) Stock Holdings Increased by Daymark Wealth Partners LLC

Daymark Wealth Partners LLC lifted its holdings in STERIS plc (NYSE:STE) by 0.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 30,333 shares of the medical equipment provider’s stock after purchasing an additional 111 shares during the quarter. Daymark Wealth Partners LLC’s holdings in STERIS were worth $6,235,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of STE. Franklin Resources Inc. raised its stake in shares of STERIS by 171.2% during the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock valued at $191,370,000 after purchasing an additional 529,308 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in STERIS by 7,418.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 309,771 shares of the medical equipment provider’s stock valued at $75,132,000 after buying an additional 305,651 shares during the period. Swedbank AB bought a new stake in shares of STERIS during the 3rd quarter worth about $28,251,000. Benjamin Edwards Inc. lifted its stake in shares of STERIS by 2,123.2% in the 3rd quarter. Benjamin Edwards Inc. now owns 113,672 shares of the medical equipment provider’s stock worth $27,574,000 after acquiring an additional 108,559 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of STERIS by 9.5% in the third quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider’s stock valued at $270,230,000 after acquiring an additional 96,336 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.

STERIS Stock Performance

Shares of NYSE STE opened at $216.91 on Wednesday. The stock’s fifty day simple moving average is $211.79 and its 200 day simple moving average is $224.77. The stock has a market capitalization of $21.41 billion, a price-to-earnings ratio of 49.52 and a beta of 0.84. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. STERIS plc has a 52-week low of $197.82 and a 52-week high of $248.24.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the previous year, the company earned $2.03 EPS. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. As a group, sell-side analysts forecast that STERIS plc will post 9.1 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 19th. Investors of record on Tuesday, November 19th were given a $0.57 dividend. The ex-dividend date was Tuesday, November 19th. This represents a $2.28 annualized dividend and a dividend yield of 1.05%. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

Insider Buying and Selling

In related news, SVP Cary L. Majors sold 1,682 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $230.00 to $260.00 in a report on Thursday, October 24th. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Stephens reaffirmed an “overweight” rating and set a $260.00 target price on shares of STERIS in a report on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Finally, JMP Securities restated a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research report on Monday, November 18th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, STERIS has a consensus rating of “Moderate Buy” and an average target price of $262.50.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.